R&D Symposium at the CNRS in

RNS Number : 4960D

Immupharma PLC

03 December 2009

 



For Immediate Release

3 DECEMBER 2009

ImmuPharma PLC

("ImmuPharma")

R&D Symposium at the CNRS in Paris

Analyst Visit

ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, will today hold a R&D Symposium in Paris for analysts to discuss its cancer drug IPP-204106. The presentation will be given by both ImmuPharma's management team and key scientists from the Centre National de la Recherche Scientifique (CNRS), France's leading scientific research institution. 

IP-204106 is ImmuPharma's lead compound for cancer. The rights for this compound have been obtained through the Company's ongoing research collaboration with the CNRS. The molecule is a nucleolin antagonist and has a dual mechanism of action, acting both in preventing angiogenesis as well as proliferation. Preclinical data has shown that nucleolin antagonists inhibit the growth of tumours and metastasis in many cancer types. Having confirmed €1.15m of French government grants, ImmuPharma progressed clinical development plans of IPP-204106 during 2009 and are likely to initiate a Phase I trial in early 2010 in cancer patients. 

No other new material information will be disclosed on the visit. The presentation will be available from Buchanan Communications. 

- Ends -

For further information please contact: 

ImmuPharma PLC	[phone]
Dimitri Dimitriou, Chief Executive Officer  Richard Warr, Chairman
Buchanan Communications	[phone]
Lisa Baderoon
Panmure Gordon & Co (NOMAD and Broker)              Andrew Burnett Rakesh Sharma	[phone]
Noble & Company Limited	[phone]
James Bromhead Sam Reynolds

Notes to Editors

About ImmuPharma PLC

ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse,  France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. 

Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009

The company also has a strong proprietary and collaborative drug development pipeline.

 

END

 

 

NRAUUGGCPUPBGQP